Generation of muscular dystrophy model rats with a CRISPR/Cas system

Scientific Reports

Volumn 4, Issue , 2015, Pages

  Nakamura, Katsuyuki ^a   Fujii, Wataru ^a   Tsuboi, Masaya ^a   Tanihata, Jun ^b   Teramoto, Naomi ^a   Takeuchi, Shiho ^a   Naito, Kunihiko ^a   Yamanouchi, Keitaro ^a   Nishihara, Masugi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN;

ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DIAPHRAGM; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENETICS; HEART; MALE; METABOLISM; MUTATION; PHENOTYPE; PHYSIOLOGY; RAT; SKELETAL MUSCLE; WISTAR RAT;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DIAPHRAGM; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; HEART; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; PHENOTYPE; RATS; RATS, WISTAR;

EID: 84907926201     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05635     Document Type: Article

References (30)

1. Koenig, M., Monaco, A. P. & Kunkel, L. M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-228 (1988).
2. Hoffman, E. P., Brown, R. H. Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-28 (1987).
3. Vainzof, M. et al. Animal models for genetic neuromuscular diseases. J. Mol. Neurosci. 34, 241-248 (2008).
4. Kinali, M. et al. Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 76, 346-353 (2011).
5. Sekiguchi, M. et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132, 124-135 (2009).
6. Anderson, J. L., Head, S. I., Rae, C. & Morley, J. W. Brain function in Duchenne muscular dystrophy. Brain 125, 4-13 (2002).
7. Beytía Mde, L., Vry, J. & Kirschner, J. Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol. 31, 4-8 (2012).
8. Nowak, K. J. & Davies, K. E. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 5, 872-876 (2004).
9. Banks, G. B. & Chamberlain, J. S. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol. 84, 431-453 (2008).
10. Nakamura, A. & Takeda, S. Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications. J. Biomed. Biotechnol. 2011, 184-393 (2011).
11. Jacob, H. J. Functional genomics and rat models. Genome Res. 9, 1013-1016 (1999).
12. Abbott, A. Laboratory animals: the Renaissance rat. Nature 428, 464-466 (2004).
13. Geurts, A. M. et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325, 433 (2009).
14. Tesson, L. et al. Knockout rats generated by embryo microinjection of TALENs. Nat. Biotechnol. 29, 695-696 (2011).
15. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
16. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
17. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013).
18. Li, W., Teng, F., Li, T. & Zhou, Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat. Biotechnol. 31, 684-686 (2013).
19. Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31, 681-683 (2013).
20. Fujii, W., Kawasaki, K., Sugiura, K. & Naito, K. Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease. Nucleic Acids Res. 41, e187 (2013).
21. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
22. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013).
23. Briguet, A. et al. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord. 14, 675-682 (2004).
24. Willmann, R. et al. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul. Disord. 19, 241-249 (2009).
25. Li, W., Liu, W., Zhong, J. & Yu, X. Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. J. Cardiovasc. Magn. Reson. 11, 40 (2009).
26. Judge, D. P., Kass, D. A., Thompson, W. R. & Wagner, K. R. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am. J. Cardiovasc. Drugs 11, 287-294 (2011).
27. Fukada, S. et al. Genetic background affects properties of satellite cells and mdx phenotypes. Am. J. Pathol. 176, 2414-2424 (2010).
28. Blake, D. J., Weir, A., Newey, S. E. & Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329 (2002).
29. Fujii, W., Kano, K., Sugiura, K. & Naito, K. Repeatable construction method for engineered zinc finger nuclease based on overlap extension PCR and TA-cloning. PLoS One 8, e59801 (2103).
30. Nakamura, K. et al. Loss of SPARC in mouse skeletal muscle causes myofiber atrophy. Muscle Nerve 48, 791-799 (2013).